Cyprumed is a biopharmaceutical company developing oral and nasal formulations for biologics such as peptides and protein drugs.
R&D:Development of oral and nasal formulations for peptides and proteins such as GLP-1 agonist peptides, insulin, human Growth Hormone, Filgrastim, Erythropoetin.
Services:Cyprumed develops oral and nasal formulations for generic or novel biologics such as peptides and proteins. Cyprumed offers the pharmaceutical development of tablets, capsules or nasal spray formulations. Cyprumed also offers stability and degradation studies of drugs incubated with various digestive enzymes. Further in vitro permeation studies across cell cultures, intestinal or nasal mucosa can be offered.